BlackRock
SMMT icon

BlackRock’s Summit Therapeutics SMMT Stock Holding History

BlackRock’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$139M Sell
9,529,041
-124,717
-1% -$2.21M ﹤0.01% 2024
2026
Q1 		$183M Buy
9,653,758
+291,837
+3% +$4.72M ﹤0.01% 1726
2025
Q4 		$164M Buy
9,361,921
+1,998,128
+27% +$37.6M ﹤0.01% 1813
2025
Q3 		$152M Buy
7,363,793
+517,126
+8% +$12.5M ﹤0.01% 1831
2025
Q2 		$146M Sell
6,846,667
-1,550,889
-18% -$35.4M ﹤0.01% 1806
2025
Q1 		$162M Sell
8,397,556
-33,968
-0.4% -$681K ﹤0.01% 1716
2024
Q4 		$150M Buy
8,431,524
+336,839
+4% +$6.53M ﹤0.01% 1824
2024
Q3 		$177M Buy
8,094,685
+196,100
+2% +$2.74M ﹤0.01% 1731
2024
Q2 		$61.6M Sell
7,898,585
-1,924,756
-20% -$10.4M ﹤0.01% 2296
2024
Q1 		$40.7M Buy
9,823,341
+63,958
+0.7% +$254K ﹤0.01% 2564
2023
Q4 		$25.5M Buy
9,759,383
+782,464
+9% +$1.61M ﹤0.01% 2868
2023
Q3 		$16.8M Buy
8,976,919
+214,078
+2% +$408K ﹤0.01% 3041
2023
Q2 		$22M Buy
8,762,841
+6,917,788
+375% +$12.6M ﹤0.01% 2988
2023
Q1 		$3.23M Buy
1,845,053
+1,310,393
+245% +$3.57M ﹤0.01% 3831
2022
Q4 		$2.27M Buy
534,660
+113,574
+27% +$207K ﹤0.01% 4087
2022
Q3 		$500K Buy
421,086
+118,878
+39% +$134K ﹤0.01% 4732
2022
Q2 		$302K Sell
302,208
-1,062,985
-78% -$1.49M ﹤0.01% 4921
2022
Q1 		$3.34M Sell
1,365,193
-35,547
-3% -$89.6K ﹤0.01% 4163
2021
Q4 		$3.77M Buy
1,400,740
+200,150
+17% +$962K ﹤0.01% 4122
2021
Q3 		$6.01M Buy
1,200,590
+105,443
+10% +$757K ﹤0.01% 3882
2021
Q2 		$8.17M Buy
1,095,147
+348,045
+47% +$2.28M ﹤0.01% 3711
2021
Q1 		$4.38M Buy
747,102
+16,492
+2% +$106K ﹤0.01% 4000
2020
Q4 		$3.43M Buy
+730,610
New +$3.09M ﹤0.01% 3850

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock's SMMT Position: Q2 2026 in Review

BlackRock reduced its Summit Therapeutics (SMMT) stake by 1.3% in Q2 2026, selling an estimated $2.21M and leaving 9,529,041 shares worth $139M. The position accounts for ﹤0.01% of the portfolio, ranked #2024.

BlackRock first reported a position in SMMT in Q4 2020 and has held it in 23 quarters since. The position peaked at $183M in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • BlackRock held 9,529,041 shares of Summit Therapeutics worth $139M as of Q2 2026.
  • BlackRock sold 124,717 Summit Therapeutics shares in Q2 2026, an estimated $2.21M.
  • Summit Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2024 holding.
  • BlackRock first reported a position in Summit Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • BlackRock's Summit Therapeutics position peaked at $183M in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.